10x Genomics (TXG) Net Cash Flow (2018 - 2026)

10x Genomics (TXG) has 9 years of Net Cash Flow data on file, last reported at $16.4 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 50.15% year-over-year to $16.4 million; the trailing twelve-month figure through Mar 2026 stood at $112.9 million (up 430.62% YoY), and the FY2025 full-year result was $129.4 million, up 959.73% from the prior year.
• Net Cash Flow declined to $16.4 million in Q1 2026, from $41.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $112.4 million in Q1 2023 to a low of -$275.9 million in Q1 2022.
• A 5-year average of -$6.2 million and a median of $16.4 million in 2026 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow slumped 903.58% in 2022 and jumped 1051.66% in 2025, its largest moves.
• Tracing TXG's Net Cash Flow over 5 years: stood at -$14.4 million in 2022, then soared by 407.79% to $44.5 million in 2023, then plunged by 221.03% to -$53.8 million in 2024, then jumped by 176.57% to $41.2 million in 2025, then sank by 60.23% to $16.4 million in 2026.
• Business Quant data shows TXG's Net Cash Flow at $16.4 million in Q1 2026, $41.2 million in Q4 2025, and $35.0 million in Q3 2025.